Search company, investor...

Inhibitex

inhibitex.com

Founded Year

1994

Stage

PIPE - II | IPO

Total Raised

$83.55M

About Inhibitex

Inhibitex is a biopharmaceutical company that is pursuing the development and commercialization of products for the infectious disease market. Inhibitex has a proprietary technology platform that utilizes antibodies to fight bacterial infections.

Headquarters Location

9005 Westside Parkway

Alpharetta, Georgia, 30004,

United States

678-746-1100

Missing: Inhibitex's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Inhibitex's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Inhibitex Patents

Inhibitex has filed 8 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/4/2004

3/29/2016

Immunology, Immune system, Vaccines, Calcium channel blockers, Clusters of differentiation

Grant

Application Date

3/4/2004

Grant Date

3/29/2016

Title

Related Topics

Immunology, Immune system, Vaccines, Calcium channel blockers, Clusters of differentiation

Status

Grant

Latest Inhibitex News

Merck Scoops Up Idenix in $3.85B Buyout

Jun 9, 2014

Submit to Hacker News Idenix Pharmaceuticals nearly became a footnote in the hepatitis C drug race a few years ago when Bristol-Myers Squibb’s buyout of Inhibitex imploded, kickstarting a series of events that led the FDA to slap clinical holds on two of the Cambridge, MA-based company’s drug prospects. Those who stayed with Idenix through the tough times are reaping the rewards today, however, as Merck has agreed to buy the company in a $3.85 billion deal. Merck is paying a whopping $24.50 per share, all in cash, for the rights to Idenix (NASDAQ: IDIX )—a more than 230 percent premium to the company’s $7.34 per share closing price on Friday. Both companies’ boards have approved the deal, which is expected to close in the third quarter. The deal marks an outcome that wouldn’t have seemed possible only a couple of years ago. Idenix is one of a number of companies trying to whip up drugs that would be part of all-oral cocktail regimens for hepatitis C, which are replacing interferon-based therapies. But in August 2012, the FDA slapped clinical holds on Idenix’s two most advanced compounds, IDX184 and IDX19368. Both drug candidates shared certain structural similarities to the drug Bristol-Myers got when it acquired Inhibitex —a drug that was linked with such serious safety concerns in a mid-stage trial that Bristol terminated the study, tossed the compound, and wrote off the Inhibitex deal . Shortly after the Bristol revelation, the FDA put holds on the two Idenix drugs , requesting all sorts of tests to ensure they were safe. Idenix shares were slammed, and the company had to regroup. Idenix pivoted, and focused on some other prospects in its pipeline, like IDX-719, a so-called NS5A inhibitor now known as samatasvir, and preclinical drug candidates IDX21437 and IDX21459. Though it would have no shot to be part of the first wave of new hepatitis C therapies—Gilead Sciences (NASDAQ: GILD ), for instance, won FDA approval of sofosbuvir (Sovaldi) last year , and other drugs from AbbVie (NYSE: ABBV ) and Enanta Pharmaceuticals (NASDAQ: ENTA ) are coming—Idenix hoped to ultimately produce drugs that could be part of regimens for all subsets of hepatitis C patients, and thus compete with the Gileads and AbbVies of the world. (It’s also sued Gilead for patent infringement, as has Merck. ) Merck, which is developing a group of next-wave hepatitis C drugs of its own, is buying into that strategy today. “Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in nucleoside/nucleotide chemistry and prodrug technologies,” said Merck research chief Roger Perlmutter (pictured above), in a statement. “Idenix’s investigational hepatitis C candidates complement our promising therapies in development and will help advance our work to develop a highly effective, once-daily, all oral, ribavirin-free, pan-genotypic regimen that has a duration of treatment as short as possible for millions of patients in need around the world.” Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail him at bfidler@xconomy.com Follow @benthefidler Share or Leave a Comment

Inhibitex Frequently Asked Questions (FAQ)

  • When was Inhibitex founded?

    Inhibitex was founded in 1994.

  • Where is Inhibitex's headquarters?

    Inhibitex's headquarters is located at 9005 Westside Parkway, Alpharetta.

  • What is Inhibitex's latest funding round?

    Inhibitex's latest funding round is PIPE - II.

  • How much did Inhibitex raise?

    Inhibitex raised a total of $83.55M.

  • Who are the investors of Inhibitex?

    Investors of Inhibitex include SR Capital Partners, BAM Elevate, Abingworth, Baker Brothers Investments, T. Rowe Price and 27 more.

  • Who are Inhibitex's competitors?

    Competitors of Inhibitex include Elusys Therapeutics, Zalicus, Vaccinogen, Zyngenia, Anadys Pharmaceuticals and 11 more.

Compare Inhibitex to Competitors

G
GangaGen

GangaGen is a biotechnology company focused on the development of products for the prevention and treatment of bacterial infections, particularly infections that are resistant to antibiotics, through the application of contemporary molecular and clinical sciences.

E
Exigent Pharmaceuticals

Exigent Pharmaceuticals is a new biopharmaceutical company focused on the development and commercialization of anti-infectives. Exigent is currently developing new pharmaceuticals to treat drug-resistant bacterial infections, using its technology platform.

T
Topigen Pharmaceuticals

Topigen is a biopharmaceutical company developing several new classes of drugs for respiratory disorders based upon its platform technology using DNARNA chemistry. These drugs are focused on inhibiting multiple inflammatory pathways at the cellular site of inflammation using a single drug product. Per the company, this approach has shown promising preclinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma COPD and allergic rhinitis AR.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Sagimet Biosciences Logo
Sagimet Biosciences

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.